Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of CC-220 in active systemic lupus erythematosus
2016-004574-17Phase 2Active
- Sponsor
- Celgene Corporation
- Start
- Apr 2017
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of iberdomide in systemic lupus erythematosus (SLE) (4 arms), sponsored by Celgene Corporation. Primary endpoint: SRI(4) response at Week 24. Started Apr 2017; status: active.
02
Drugs
iberdomide
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2016-004574-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004574-17.